Compare CPA & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPA | KYMR |
|---|---|---|
| Founded | 1947 | 2015 |
| Country | Panama | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.8B |
| IPO Year | 2005 | 2020 |
| Metric | CPA | KYMR |
|---|---|---|
| Price | $122.31 | $81.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 26 |
| Target Price | ★ $164.29 | $108.04 |
| AVG Volume (30 Days) | 394.9K | ★ 710.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 5.45% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,211,000.00 |
| Revenue This Year | $13.41 | $16.05 |
| Revenue Next Year | $7.38 | $4.79 |
| P/E Ratio | $9.05 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $82.54 | $19.45 |
| 52 Week High | $156.41 | $103.00 |
| Indicator | CPA | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 32.78 | 47.15 |
| Support Level | $122.10 | $77.78 |
| Resistance Level | $122.76 | $95.90 |
| Average True Range (ATR) | 5.16 | 4.43 |
| MACD | -2.50 | -1.09 |
| Stochastic Oscillator | 9.21 | 14.60 |
Copa Holdings SA is a provider of airline passenger and cargo services through its subsidiaries. The company operates through the air transportation segment. It offers international air transportation for passengers, cargo, and mail, operating from its Panama City hub in the Republic of Panama, and domestic and international air transportation for passengers, cargo, and mail with a point-to-point route network through Copa Colombia, a Colombian air carrier. The company's geographical segments are North America, South America, Central America, and the Caribbean. It derives the maximum revenue from North America.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.